Groundbreaking Study Offers New Hope for Treatment-Resistant PTSD

Veterans struggling with severe post-traumatic stress disorder who have found no relief from conventional treatments may have a new path forward. The first U.S. clinical trial examining psilocybin-assisted therapy for veterans with PTSD has shown remarkable results, with three-quarters of participants achieving remission within one month of completing treatment.

Published in Communications Medicine, the study from The Ohio State University's Center for Psychedelic Drug Research and Education tracked 12 veterans through an 11-week protocol. Researchers found an average reduction of 27.5 points in clinician-rated PTSD symptoms, with nine participants meeting the criteria for remission. Importantly, the treatment protocol proved safe, causing no serious adverse events and no increases in suicidal thinking.

More Than Just Medicine

The treatment approach combines rigorous psychotherapy with carefully administered doses of synthetic psilocybin, the active compound found in magic mushrooms. Participants underwent eight hours of preparatory psychotherapy before receiving two doses—15 milligrams followed by 25 milligrams—then completed six to eight additional hours of integrative therapy to process their experiences.

According to study director Dr. Alan Davis, associate professor of social work at Ohio State, the therapy component is essential to the treatment's effectiveness. Evidence from the trial showed PTSD symptoms began decreasing even before the psilocybin was administered, suggesting the combined approach creates lasting change.

"This treatment is more than just a drug," Davis explained. "The drug itself is a catalyst for the deep work that opens a window for people to perhaps access things they wouldn't be able to access emotionally otherwise."

A Veteran's Journey to Healing

Zachariah Collett, a U.S. Army veteran who served a 28-month combat tour in Iraq, was among the study participants. After being medically retired at age 25 with multiple service-connected disabilities including PTSD, Collett spent years battling nightmares, anger, and an inability to find peace. Traditional counseling and medications provided no relief.

Three years after completing the psilocybin-assisted therapy, Collett describes its profound and lasting impact on his life, family, and marriage. "It allowed me the opportunity to create peace, and stillness, and acceptance, and forgiveness and grace—all those things opposite of resentment and anger and hatred," he said.

Addressing an Urgent Need

The overwhelming response to the study underscores the desperate need for effective PTSD treatments among veterans. More than 3,600 veterans reached out during recruitment, though only 12 could ultimately participate in this pilot trial. Lead researcher Stacey Armstrong, senior researcher at Ohio State's Center for Psychedelic Drug Research and Education, emphasized that current treatments leave too many veterans suffering.

"While treatments do work for some veterans with PTSD, they're falling short for many, leaving veterans to continue to search for solutions, which can lead to treatment dropout, long-term disability and elevated suicide risk," Armstrong noted.

The research team is now seeking funding for a larger randomized controlled trial to build on these promising preliminary findings and potentially bring new hope to the countless veterans still struggling with treatment-resistant PTSD.

This article is based on reporting by Ohio State News.